SpaceX~$1TSpaceX~$1T
Insider Buying
Subscribe
All stock lists
DCOY

Decoy Therapeutics Inc. (DCOY)

NASDAQ: DCOY · USD
Healthcare · Biotechnology
$0.83-$0.04 (-4.68%)
 
Market cap
$1.98M
Insider Score
Market Cap$1.98M-90.8%
Revenue (ttm)$535.06K
Net Income-$16.56M
EPS$31.19
Shares Out2.39M
PE Ratio0.03
Forward PE-0.09
Dividendn/a
Ex-Dividend Daten/a
Volume37,738
Open$0.86
Previous Close$0.87
Day's Range$0.80 - $0.87
52-Week Range$0.80 - $16.92
Beta0.74
Analystsnone
Price Target$3.00(+261.71%)
Earnings Daten/a
-4.61% (1D)
No price history available.

About DCOY

Decoy Therapeutics Inc. operates as a pre-clinical stage biotechnology company. It focuses on advancing the peptide conjugate therapeutics through its Immediate Peptide/PPMO/P-PROTAC Alpha-helical Conjugate Technology (IMP3ACT) platform that leverages peptide coiled-coils chemistry and physics to design a-helical peptides through computational and ML tools. The company's IMP3ACT platform leverages machine learning and artificial intelligence tools alongside synthesis techniques to engineer, enhance, and manufacture peptide conjugates targeting various unmet medical needs. It focuses on building a portfolio of peptide conjugate therapeutics focusing on infectious diseases and oncology. The company was formerly known as Salarius Pharmaceuticals, Inc. and change its name to Decoy Therapeutics Inc. in January 2026. Decoy Therapeutics Inc. is based in Houston, Texas.

Address
2450 Holcombe Blvd, Houston, TX, 77021, United States
Market Cap
2 million
Employees
11
Industrial Classification
Biotechnology

What Are Insiders Doing?

Open-market buy / sell balanceNet Buying
Sold
$17.28
Bought
$19.75K

View the trades behind this meter — each links to its SEC Form 4 →

Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.

1 Day
-4.71%
5 Days
-14.97%
1 Month
-19.51%
6 Months
-88.64%
1 Year
-90.79%

$DCOY stock is featured in our Insider Trades datasets.

→ All Stock Lists

Recently reported changes in DCOY holdings by institutional investors

Scanning latest 13F filings…

Latest 0 13F filings · Source: SEC EDGAR

View all institutional owners →

Insider Trading

Quarterly net insider trading by DCOY's directors and management

Net Shares Purchased by Insiders−30k−15k02025Q42026Q12026Q22026Q32026Q4

Source: SEC EDGAR (Form 4)

Corporate Lobbying

DCOY Estimated quarterly lobbying spending

Source: U.S. Senate LDA

DCOY Revenue by Segment

$4.95MTotal
Loss from operations$3.01M60.89%
Professional services and Consulting$810.45K16.38%
Personnel cost$695.21K14.05%
Grant Revenue$307.43K6.21%
Facility cost and other$122.03K2.47%

As of: Q3 2026 (Sep 30, 2026) · Source: SEC EDGAR (10-Q)

U.S. Patents

New DCOY patent grants

Loading patent grants…

Source: USPTO Open Data Portal

Government Contracts

Estimated quarterly amount awarded to DCOY from public contracts

Source: USAspending.gov

Bull Case vs Bear Case

AI-generated from DCOY’s recent data — informational, not investment advice

Generating analysis…

What’s Behind the Score

Insider Activity
60% of score
0
Analyst Ratings
40% of score
60
News & Sentiment
No data yet
—

Recent Insider Activity

Buys
2
Sells
2
Buy Value
$19.75K
Distinct Buyers
2

Frequently Asked Questions

Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.

ETFs that hold this stock

MEDXHorizon Kinetics Medical ETF0.00%

Weight is the stock’s share of each fund’s holdings.